CD2 regulates responsiveness of activated T cells to interleukin 12 [published erratum appears in J Exp Med 1995 Oct 1;182(4):1175] by unknown
CD2 Regulates Responsiveness  of Activated T  Cells 
to Interleukin  12 
By Jared A. Gollob,* Jing Li,* Ellis L. Reinherz,r 
and Jerome Ritz* 
From the *Division of Hematologic Malignancies, and *Laboratory of Immunobiology, 
Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, 
Boston, Massachusetts 02115 
Summary 
Interleukin (IL) 12 is a 70-kD heterodimeric cytokine produced by antigen-presenting cells (APCs) 
such as macrophages in response to infectious pathogens and interferon (IFN) 3'. The varied 
immunomodulatory effects of I1-12 include the stimulation of proliferation and IFN-3, produc- 
tion by T  cells, and it also has a central role in the development of the T  hdper cell type 1 
immune phenotype. We undertook the production of antibodies capable of modulating the re- 
sponse of T  ceils to II.-12, and in the process we discovered two antibodies that inhibited the 
ability of II-12 to stimulate T cell proliferation. In this report, we demonstrate that these anti- 
bodies recognize CD2, and we show how antibodies directed toward either the adhesion domain 
of CD2 or its ligand, CD58, specifically inhibit I1-12-induced proliferation and IFN-'y produc- 
tion by phytohemagglutinin-activated T cells, leaving the response to I1-2 unaffected.  A three- 
to fourfold reduction in proliferation and IFN-3~ production was observed at I1-12 concentrations 
as high as 1 nM, with complete inhibition occurring at ~<1 pM. This novel effect is not directly 
mediated at the level of the I1-12 receptor, as shown by the inability of these antibodies to block 
I1-12 binding to activated T  cells. Furthermore, by using activating pairs of CD2 antibodies, 
we show that CD2 stimulation strongly synergizes  with I1-12, even at 0.1 pM, in inducing 
both T  cell proliferation and IFN-~,  production. Cytolytic T  lymphocyte-associated antigen 
4-immunoglobulin-mediated inhibition of the B7/CD28 interaction did not affect the T  cell 
response to either I1-12 or I1-2, but the removal of APCs selectively diminished the proliferative 
response to I1-12. Based on this data, we hypothesize that CD2 has a central role in an I1-12/IFN-3, 
positive feedback loop between T cell and APC, providing the key functional link via a CD2/CD58 
interaction that controls T cell responsiveness to I1-12. This model provides a basis for future 
investigations aimed at defining the signaling mechanisms that mediate this cytokine-specific 
regulatory effect of CD2, and it offers insight into how a cytokine receptor and distinct adhesion 
molecule can interact to modulate responsiveness to that cytokine. In addition, it underscores 
the possibility that the clinical potential of an immunomodulatory  drug like I1-12 may be governed 
by the presence or absence of specific costimulation. 
I 
1-12 is a disulfide-linked,  70-kD heterodimeric cytokine, 
composed of a 35-kD and a 40-kD subunit (1). Its produc- 
tion was first noted in EBV-transformed  B cell lines stimu- 
lated by phorbol esters, but, in addition to B cells, a primary 
source is macrophages stimulated by bacterial products, in- 
tracelhlar parasites,  and IFN-~/  (2).  I1-12 has a variety of 
immunomodulatory  effects on T and NK cells, most notably 
involving the stimulation of IFN-3, production (3), prolifer- 
ation (4), and cytolytic activity (5, 6). In addition, I1-12 plays 
a central role in the development of the Thl immune response 
(7), characterized  by IFN-'y and I1-2 production by T cells, 
and in the subsequent enhancement of cellular  immunity 
directed in particular toward intracellular pathogens (8, 9). 
Apart from the unique effect on Thl development, there is 
considerable overlap between the functional effects of II.,12 
and I1-2 on T and NK cells, although important differences 
do exist. For example, the proliferative effect of I1-12 on T 
and NK cells is weaker when compared with I1-2 (1, 4), while 
I1-12 is a more potent inducer of IFN-3' (3).  In addition, 
NK cell cytolytic activity induced by I1-2 is greater than that 
observed with II.-12 (5). While these differences most likely 
reflect, at least in part, differences in signaling through the 
I1-12R and Ib2R, they may also, from a physiologic stand- 
point, be artificial,  in that optimal stimulation by either 
cytokine may require specific costimulatory signals that can 
be absent from in vitro assays. This possibility was illustrated 
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tion augments, in a synergistic fashion, the response (including 
proliferation and IFN-qr production) of resting and activated 
T cells to I1:12 (10). Through this synergy, T cell prolifera- 
tion exceeded the maximal proliferation induced by I1:2. This 
suggested that  the optimal physiologic response of T  cells 
to II.-12 was in part dependent on costimulatory signals de- 
livered through an interaction with APCs. In theory, there- 
fore, specific costimulation could be the key factor in deter- 
mining to what extent and under which circumstances a T 
or NK cell will respond to cytokines with similar properties, 
such as I1:12  and I1:2. 
CD2 (Tll) is a 50-kD surface glycoprotein present on T 
and NK cells. Although much is known concerning the struc- 
ture and expression of CD2, its functional significance has 
not been fully delineated.  CD58 has been identified as a ligand 
for CD2, interacting with the adhesion domain of CD2 (11, 
12). Cellular adhesion between T cells and APCs, mediated 
in part through  the CD2/CD58  interaction,  facilitates  an- 
tigen recognition and subsequent T cell activation (13). NK 
cell cytolytic activity is also, in some instances,  partially de- 
pendent on the CD2/CD58-mediated adhesion between NK 
cell and its target (14). The CD2R epitope appears primarily 
on activated T  cells (15)  and,  to a much lesser degree,  on 
activated NK cells.  There is no known ligand  for CD2R. 
Although CD58 does not interact directly with CD2R, aner- 
gized T  cells can regain  responsiveness to alloantigen  plus 
CD58 costimulation when expression of the CD2R epitope, 
down-regulated during  anergy,  is restored after prolonged 
culture in I1:2 (16). A more direct role for CD2 in lympho- 
cyte activation has been suggested by the observation that 
the pair of anti-CD2 plus anti-CD2R mAbs or CD58 plus 
anti-CD2R can activate T cells, resulting in I1:2 production, 
up-regulation of the I1:2R, and proliferation (15). This stim- 
ulation reduces the threshold for T  cell activation through 
the T cell receptor (17) and can activate the cytolytic pathway 
in T and NK cells (18). In addition, antibodies to CD2 have 
been reported to diminish  the proliferation  of activated T 
cells (19). 
In the course of developing antibodies capable of modulating 
the functional effects of I1:12, we discovered two antibodies 
that individually had a potent, selective inhibitory effect on 
the Ib12-induced proliferation of activated T cells. These an- 
tibodies were found to recognize  the adhesion  domain  of 
CD2 and CD2R. By examining the effects of these and other 
CD2  mAbs  on  I1:12-  and  Ib2-induced  proliferation  and 
IFN-3' production by T cells, we show that the response of 
T  cells to I1:12 and I1:2 is differentially regulated by CD2. 
Materials  and Methods 
Isolation and Culture ofT Cells.  PHA-activated T cells were pre- 
pared from  heparinized blood obtained  from normal  volunteer 
donors by first isohting PBMC on Hcoll-Hypaque (Pharmacia LKB, 
Uppsala, Sweden) gradients. Whole PBMC were then cultured at 
a  starting  concentration  of 1  x  106 cells/m1 in  RPMI  1640 
medium (Sigma Chemical Co., St. Louis, MO) supplemented with 
15% FCS (Proteins Antibodies Antigens Laboratories, Newport 
Beach, CA),  2% t-glutamine  (BioWhittaker,  Inc.,  Walkersville, 
MD), 1% sodium pyruvate (Sigma Chemical Co.), 1% penicillin- 
streptomycin (BioWhittaker, Inc.), 1% gentamicin (Life Technol- 
ogies, Inc., Grand Island, NY), and 2.5/~g/ml PHA (Murex, Dart- 
ford,  UK).  Cells  grown  in  this  manner  were  90-95% 
CD3+CD56 -, 0% CD56+CD3 -, and 1-2% CD14+CD3 - when 
analyzed by flow cytometry on days 2-4. For the preparation  of 
sorted,  PHA-activated T cells, whole PBMC were stained with 
CD5-PE and Ia-FITC  and sorted  for CD5+Ia -  calls on a flow 
cytometer (EPICS 752; Coulter Corp., Hialeah, FL). Before sorting, 
cells were 8%  CD3-  Ia + and  92%  CD3+Ia -.  After  sorting, 
99.8% were CD3+Ia -  and <0.2% CD3-Ia +. These sorted ceils 
were cultured  in PHA in the same manner  as whole PBMC. 
Production ofCD2 mAbs.  BALB/c mice were immunized with 
day 2-4 PHA-activated T cells. Fusions using BALB/c splenocytes 
and the NS-1 myeloma cell line were carried out as previously de- 
scribed (20), and hybridomas were screened in proliferation assays 
using day 4-5 PHA-activated T cells stimulated with 1 pM Ib12 
in the presence of a 1:4 dilution  of each tested supernatant  (per- 
formed in duplicate).  Two hybridomas, later designated CD2E1 
(IgG1) and CD2E3 (IgM), were sdected for their ability to inhibit 
II.,12-induced proliferation by >50%. These were each subcloned 
twice by limiting  dilution. 
Antibodies.  Purified unconjugated and FITC- or PE-conjugated 
murine  mAbs  obtained  from Coulter Corp.  include T1  (CD5, 
IgG2a), T3 (CD3, IgG1), My4 (CD14, IgG2b), I2 (Ia), and NKH1 
(CD56,  IgG1). Anti-T11-1 (CD2, IgG2b) was used as a dilution 
of ascites, while  purified  anti-T11-2  (CD2,  IgG2),  anti-T11-3 
(CD2K, IgG3), and CD2E1 (IgG1) mAbs were isolated from as- 
cites by aiTmity chromatography using either protein A or protein 
G (Pharmacia LKB) columns. The anti-T11-1 and anti-T11-3 mAbs 
were conjugated to fluorescein as previously described (21). Purified 
CD2E3 (IgM) and 8C12 (CD18,  IgM) mAbs were obtained by 
ammonium sulfate  precipitation of ascites followed  by dialysis against 
PBS. TS 2/9 (CD58, IgG1) was kindly provided by Dr. T. Springer 
(Center for Blood Research, Boston, MA) and was used as a dilu- 
tion of ascites. Purified cytolytic T lymphocyte-associated antigen- 
4-Ig I and an isotype-matched control were kindly provided by Dr. 
Vassiliki Boussiotis (Dana-Farber Cancer Institute,  Boston, MA). 
Cell Lines.  The control (C33) and CD2-expressing  (W33) T 
cell lines were generated by infecting the murine T cell hybridoma 
MLV) (23) containing either TKneo vector (24) alone or TKneo- 
CD2 sequence, respectively.  The htter contains the full length wild- 
type human CD2 eDNA as previously described (11). C33 and W33 
were selected  by culturing under 1/~g/ml neomycin growth medium 
(RPMI 1640 with 10% FCS, 1% penicillin-streptomycin, and 1% 
t-glutamine).  CD2 expression on W33 was further maximized by 
three anti-CD2  mAb dynabead separations after neomycin selec- 
tion.  The surface expression of CD2 on W33 was confirmed by 
indirect immunofluorescence. Once established, both cell lines were 
maintained in 0.5 mg/ml neomycin growth medium. 
Cytokines.  All cytokines were recombinant  human  proteins. 
I1.,12 (specific activity 5.26  x  106 U/rag) was kindly provided by 
Dr. Stanley Wolf (Genetics Institute, Cambridge, MA). IL-2 (3.9 x 
106 U/ml) was kindly provided by Amgen Biologicals (Thousand 
Oaks,  CA). 
Imraunofluorescence Analysis.  Samples  of cells were stained di- 
rectly or indirectly with FITC- or PE-conjugated mAb, washed, 
1Abbreviations used in  this paper: CAM, cellular adhesion molecule; 
CTLA-4, cytolytic  T lymphocyte-associated  antigen 4; E-rosetting, eryth- 
rocyte rosetting; FGFR, fibroblast  growth factor receptor; RAM, rabbit 
anti-mouse. 
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scribed previously (5). 
Proliferation  Assays.  Day 3-5 T cells  preactivated  with PHA were 
plated at 20,000 cells per well in 96-well U-bottom microtiter plates 
(Flow Laboratories,  Inc., McLean,  VA) in medium alone or medium 
containing cytokine  and/or mAb(s) as indicated.  Purified  anti-T11-2, 
anti-T11-3, CD2E1, CD2E3, and anti-CD18 mAbs were used at 
effective  final concentrations ranging from 5-15/zg/ml, while anti- 
Tl1-1 and anti-CD58 mAbs were used as ascites at a final dilution 
of 1:400. Purified CTLA-4-Ig was used at a final concentration of 
5/zg/ml. Cells were not preincubated with mAbs before adding 
cytokine. Medium consisted  of RPMI 1640 plus 15% FCS. Samples 
were cultured in triplicate in a total volume of 200/xl per well at 
37~  in 5% CO2 for 48 h. During the last 9 h of the 48-h cul- 
ture period, cells were incubated with 1/~Ci of [3H]thymidine 
(DuPont, Wilmington, DE). The cells were harvested onto glass 
fiber filters using a harvester (96 Mach II; Tomtec, Orange, CT), 
and the radioactivity on the dried filters was measured in a liquid 
scintillation counter (1205 Betaplate; Pharmacia LKB, Uppsala, 
Sweden). Results represent the mean of triplicate wells and are ex- 
pressed as counts per min of [3H]thymidine incorporation. 
IFN-7 Assays.  Day 3-5 T cells preactivated with PHA were 
plated at 30,000 cells per well in 96-well U-bottom microtiter plates 
using conditions identical to those used in the proliferation assays 
except that samples were cultured in duplicate. Supernatants were 
harvested after a 72-h incubation and assayed  by ELISA (Endogen, 
Inc., Boston, MA) for production of human IFN-3'. 
Erythrocyte Rosetting (E-Rosetting) Assay.  SRBC  were prein- 
cubated for 15 min at 37~  with aminoethyl isothiouronium bro- 
mide (Sigma Chemical Co.), as previously  described (13). 1 x  10  s 
W33 ceils (CD2 transfectants) were preincubated with medium 
alone or medium plus CD2 mAb (used as ascites at 1:50 dilution) 
in a total volume of 100 #1 for 0.5 h at 4~  followed by the addi- 
tion of 10/~1 of the aminoethyl isothiouronium bromide-treated 
SRBC suspension. Tubes were incubated at 37~  for 5 min, spun 
down for 5 min at 800 rpm,  and incubated for 45 min at 4~ 
The cell pellet of each tube was gently resuspended, and 100 ceils 
were counted under a light microscope  (American  Optical Scientific 
Instruments, Buffalo,  NY). W33 cells  bound to at least five  SRBC 
were counted as rosette positive. 
1251-11_,I2  Binding Assays.  Ib12 was 12sI labeled to a specific ac- 
tivity of 1.4  x  10  + dpm/pmol using  the  Iodo-Bead method 
(Pierce, Rockford, IL). Successful  radioiodination was confirmed 
by subjecting the labeled  product to SDS-PAGE analysis  (7.5% gel, 
reduced and nonreduced conditions), and the tzI-I1-12 was quan- 
titated using a protein assay  reagent kit (Micro BCA; Pierce, Rock- 
ford,  IL).  The preservation of bioactivity after iodination was 
confirmed by using the 12sI-IL-12 in a proliferation assay with 
PHA-activated T cells and comparing the result with cold IL-12 
used in the same assay. For binding assays, 1-1.5 106 cells were in- 
cubated at 4~  for 2 h with I~I-IL-~2 at serial dilutions ranging 
from 16 pM to 8 nM in binding medium containing RPMI 1640 
plus 1% BSA, 25 mM Hepes, and 0.1% sodium azide, pH 7.4. 
Nonspecific binding was determined in the presence of a 150-fold 
excess of  unlabeled  IL-12. The effects  of CD2E1, CD2E3, and CD18 
mAbs on 1I.-12 binding were examined by incubating ceils with 
25/zg/ml of each mAb for 0.5 h at 4~  before adding the 12sI- 
Ib12.  IL-12 binding was analyzed by Scatchard plot and by the 
Ligand program (Biosoft, Ferguson, MO) (25). 
Iraraunoprecipitation.  Day 3-4 PHA-activated T cells (5  x  106 
cells per lane) were surface labeled with t~I using the lactoperox- 
idase method. Radiolabded cells were washed and solubilized in 
I ml lysis  buffer (1% NP-40, 50 mM Tris-HC1, pH 8.15, 150 mM 
NaCI, I mM EDTA, I mM PMSF, 2/zg/ml pepstatin A, 10/zg/ml 
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aprotinin, and 10/~g/ml leupeptin). Lysates  were precleared with 
fixed Staphylococcus  aureus cowan I (Calbiochem, La  Jolla, CA) and 
rabbit anti-mouse Ig (RAM)-coupled protein A beads, followed 
by incubation  with specific  mAbs for 4 h and incubation  with RAM- 
coupled protein A beads for an additional 4 h. Immunoprecipitates 
were washed extensively and subjected to SDS-PAGE analysis on 
a 7.5% gel. 
Results 
Development of Two Antibodies Modulating the Proliferative 
Response of T  Cells to 11_,12; CD2EI and CD2E3 Recognize 
CD2 and CD2R.  To investigate the mechanisms by which 
IL-12 exerts its heterogeneous immunomodulatory effects on 
T cells, we devised a strategy to produce antibodies against 
structures expressed on the surface of activated T  cells that 
would be capable of modulating the T cell response to I1:12. 
Since PHA-activated T cells up-regulate expression of the I1: 
12R and respond to I1:12 (26), they were used to immunize 
mice in preparation for the development of hybridomas. Hy- 
bridoma supernatants were then screened for their ability to 
inhibit the proliferative response of PHA-activated T cells to 
Ib12. 1,200 hybridomas were screened, and, as shown in Fig. 
1 A, two (later designated CD2E1 and CD2E3) were selected 
for  their  ability to  inhibit  Ib12-induced proliferation by 
40-50%. After subcloning, immunoprecipitations were per- 
formed with both mAbs using surface-labeled PHA-activated 
T cells, and each precipitated a single band of ,,o50 kD (data 
not shown). CD2E1 stained resting T cells strongly and was 
further up-regulated with PHA activation, whereas CD2E3 
exhibited only weak staining with resting T  cells but was 
strongly up-regulated with activation (data not shown). These 
results together suggested that CD2 was the protein being 
recognized by both mAbs, and this was confirmed by staining 
a CD2 transfectant (Fig. 1 B). The staining pattern on resting 
and activated T cells, along with the observation that CD2E1 
but not CD2E3 blocks E-rosetting (data not shown), indi- 
cated that CD2E1 and CD2E3 recognized the adhesion do- 
main of CD2 and CD2R, respectively.  As demonstrated in 
Fig.  1 C, CD2E1  and CD2E3 were only able to partially 
block the staining of a CD2 transfectant with FITC-conjugated 
anti-T11-1 and anti-T11-3, respectively, showing that the epi- 
topes recognized by these new mAbs are unique. 
CD2EI and CD2E3 Selectively Inhibit IL12-induced T Cell 
Proliferation and IFN-7 Production.  After identifying CD2E1 
and CD2E3 as being specific for different CD2 epitopes,  we 
investigated whether the inhibitory effect on proliferation was 
specific for II:12 and whether IFN-3, production was affected 
in a similar manner. Since I1:12 and I1:2 elicit similar bio- 
logic effects from preactivated T cells, we tested purified prepa- 
rations of these antibodies against a wide range of concentra- 
tions of both cytokines. Fig. 2 A shows that both antibodies 
had a potent, selective inhibitory effect on the I1:12-induced 
proliferation of PHA-activated T cells. Even at an I1:12 con- 
centration of 1 nM, there was nearly a fourfold reduction 
in proliferation, with complete inhibition observed at ~<1 pM. 
The maximal effect of the antibodies was reached at a con- 
centration of 5-10/~g/ml (data not shown). An identical, 
I1:12-specific  inhibitory effect was observed with regard to Figure 1.  (A) Supematants from hybridomas 20B6 and 7F12  (later desig- 
nated CD2E1 and CD2E3, respectively)  inhibit  the ID12-induced prolifer- 
ation of PHA-activated T cells. All supernatants were tested at a final dilu- 
tion of 1:4 together with I pM Ib12 in 48-h proliferation  assays, as described 
in Materials and Methods. The negative hybridomas compared with 7F12 
and 20B6 represent a small fraction of the 1,200 hybridomas screened. 
Proliferation in the absence of exogenous cytokine was 3,500  +  200 cpm. 
(B) CD2E1 and CD2E3  stain the CD2 transfectant W33. Both mAbs 
were used as ascites at  1:100 dilutions and compared with staining by 
anti-T11-1, anti-T11-2, and anti-T11-3. (C) CD2E1 and CD2E3 partially 
block the staining of a CD2 transfectant with anti-T11-1 and anti-T11-3, 
respectively. W33 cells were first incubated with medium alone or the 
indicated unconjugated  mAb (used as ascites at 1:100  dilution) for 20 min 
at 4~  followed by incubation  with the indicated FITC-conjugated mAb 
(used at 1:20 dilution) for an additional 20 min. Mean fluorescence inten- 
sity is noted in the upper right hand corner. 
IFN-'y production, with both mAbs causing a threefold reduc- 
tion at a concentration of 100 pM and complete inhibition 
at 1 pM (Fig. 2 B). As shown in Fig. 2, there was no significant 
effect on I1-2-induced proliferation or IFN-'y production. 
Individual Antibodies to the First Domain of CD2 and to CD2R 
Differentially Affect IL12-induced  T Cell Proliferation and IFN-g/ 
Production.  After observing the novel effect of CD2E1 and 
CD2E3  on the response of T  cells to I1-12, we examined 
whether mAbs to other CD2 epitopes behaved in a similar 
manner. Fig. 3 A demonstrates that, while anti-T11-1 (which 
recognizes an adhesion site within the first domain of CD2 
and blocks E-rosetting) had the same I1-12-specific  inhibi- 
tory effect on proliferation as CD2E1 and CD2E3, anti-T11-2 
(which interacts with a region orthogonal to the AGFCC'C" 
face of the adhesion domain) did not inhibit  the response 
to either I1-12 or IL-2. In sharp contrast, anti-T11-3 stimu- 
lated proliferation. As shown in Fig. 3 B, maximal stimula- 
tion with anti-T11-3 was in some instances independent of 
exogenous cytokine, although the proliferative effect of anti- 
Tll-3 alone varied between assays from three to nine times 
baseline proliferation. Fig. 3 B also demonstrates that CD2E1, 
CD2E3,  and anti-T11-1  all inhibited the baseline prolifera- 
tion  of preactivated  T  cells  by  50-80%.  Anti-Tll-1  and 
anti-T11-2 were also  individually tested for their effect on 
cytokineqnduced IFN-3' production, and the results once again 
mirrored those obtained in the proliferation assays (Fig.  4). 
CD2EI  and  CD2E3  Do  Not  Block  11_,I2 Binding  to  T 
Cells.  Because these two CD2 mAbs selectively blocked two 
major functional effects of II-12,  we investigated whether 
they were interfering with the binding of Ib12 to its receptor. 
Binding studies using radiolabeled I1-12 were performed on 
day 3-4  PHA-activated T  cells,  and two binding affinities 
were detected: (a) a low affinity site with a dissociation con- 
stant of -2  nM,  1,000 sites per cell, and (b) a high affinity 
site, with a dissocilation constant of ml00 pM, 350 sites per 
cell (Fig. 5 A). Compared with a control antibody, CD2E3 
had no significant effect on high or low affinity IL-12 binding 
(Fig. 5 B). CD2E1 also had no measurable effect on binding 
(data not shown). In addition to demonstrating that I1-12 
binding is not affected by our antibodies, we observed that 
radiolabeled I1-12 does not bind to a CD2 transfectant (data 
not shown), further supporting our conclusion that  CD2 
is unlikely to be a component of the I1-12R. 
Anti-CD58 Selectively Inhibits ILI2-induced T  Cell Prolifer- 
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(A) CD2E1 and CD2E3 selectively  inhibit the Ibl2-induced 
proliferation  of PHA-activated T cells. After 4 d of culture in medium 
containing PHA at 2.5/~g/ml, cells were incubated with Ib12 or IL-2, 
alone or together with the indicated purified mAb at 5-15 #g/ml, in a 
48-h proliferation assay. Anti-CD18 served as a negative control. Prolifer- 
ation in the absence of cytokine or mAb was 9,000  _+ 1,000  cpm. Results 
are representative of four experiments. (B) CD2E1 and CD2E3 selectively 
inhibit the Ib12-induced production of IFN-',/by PHA-activated T cells. 
Purified mAbs were used at 5-15/~g/ml. IFN-7 concentration was mea- 
sured with an ELISA assay after a 72-h incubation. The sensitivity of the 
assay is <5 pg/ml. The baseline production of IFN-7 in the absence of 
exogenous cytokine was 225 pg/ml. Results are representative of two ex- 
periments.  -CF-, no mAb; -.-+-.-, anti-CD18;  --0--, CD2E3; ""'&".-, 
CD2E1. 
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Figure 3.  (.4) Antibodies recognizing CD2 and CD2R differentially 
affect the Ib12 and II~2-induced proliferation of PHA-activated T cells. 
All mAbs were used as purified protein at 5-15/~g/ml except for anti-T11- 
1, which was used as ascites at 1:400 dilution. Cells were incubated with 
IL-2 or Ib12, alone or together with the indicated mAb, in a 48-h prolifer- 
ation assay. Results are representative of four experiments. --0--, no mAb; 
-.-+-.-, anti-CD18;  ....he...,  Tl1-1; .... ￿9  .... , Tll-2; --O--, Tll-3. (B) 
CD2 and CD2R mAbs affect the proliferation of PHA-activated T calls 
in the absence of exogenous cytokine. Cells were incubated alone or to- 
gether with the indicated mAb in a 48-h proliferation assay. Results are 
representative of four experiments, although the degree of stimulation  ob- 
served with anti-T11-3 alone varied between assays  from three to nine times 
baseline proliferation. 
ation and IFN-7 Production.  Having established that the mech- 
anism governing the IL-12-specific inhibitory effect of anti- 
bodies directed at the adhesion domain of CD2 and one of 
our anti-CD2R mAbs is not related to interference with Ib12 
binding, we investigated whether interference with the in- 
teraction between CD2  and its known ligand, CD58,  was 
the critical factor.  This explanation would be plausible pri- 2111111- 
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marily for CD2E1 and for anti-T11-1, both of which block 
E-rosetting,  a phenomenon reliant upon adhesion mediated 
via CD2/CD58. Using "IS 2/9, an anti-CD58 antibody which 
blocks the CD2/CD58 interaction (13), we demonstrated the 
same  potent  Ib12-specific inhibition  of proliferation  and 
IFN-'y production that was observed with CD2E1, anti-T11-1, 
and CD2E3  (Fig.  6). 
CTLA-4-Ig Does Not Inhibit II~12-induced T Cell Prolifera- 
tion.  Having established that antibodies interfering with the 
CD2/CD58  interaction  specifically  inhibit  the stimulation 
of activated T cells by II:12, we investigated  whether blocking 
the CD28/B7 interaction  had a similar effect. A recent re- 
port demonstrated how CD28 antibodies and B7 transfec- 
rants can synergize with IL-12 in inducing T  cell prolifera- 
tion and IFN-~/production  (10) but did not show whether 
the response of activated T  cells to I1.-12 is abrogated by in- 
hibiting the binding of CD28 to B7. Since CTLA-4, a second 
ligand for B7, blocks the CD28/B7 interaction  when used 
in its soluble form (CTLA-4-Ig) (27), we tested whether it 
was capable of affecting IL-12- and/or  Ib2-induced T  cell 
proliferation.  As shown in Fig. 7, CTLA-4-Ig had no effect 
on the ability of IL-12 or IL-2 to stimulate the proliferation 
of activated T  cells. 
Anti-TIl-1 Plus Anti-T11-3 Synergizes with IL12 in Inducing 
T  Cell Proliferation.  We have already shown that anti-T11- 
3, distinct from CD2E3, can stimulate proliferation to near- 
maximal levels without exogenous cytokine. However, T cell 
Figure  5.  (A) Scatchard analysis of 12sI-Ib12 binding to day 3 PHA- 
activated T cells. 1  x  106 cells were incubated with nsI-I1:12  at concen- 
trations  ranging from 8 nM to 16 pM.  Nonspecific binding was deter- 
mined in the presence of 140 nM cold I1:12 and used to calculate specific 
bound Ib12 (x-axis).  Results are representative of three experiments.  (B) 
The CD2E3 mAb does not affect the binding of II:12  to day 3 PHA- 
activated T cells. Purified CD2E3 and anti-CD18 were used at 50/~g/ml. 
Results  are representative  of two experiments. 
activation through CD2 has been attained in previous studies 
either through pairs of anti-CD2R plus anti-CD2 mAbs or 
through anti-CD2R combined with CD58. Since our results 
to this point implicated CD2 as being pivotal in determining 
T  cell responsiveness to IL-12, we investigated the manner 
in which stimulatory pairs of CD2 antibodies interacted with 
Ib12 and Ib2. When used without exogenous cytokine, the 
anti-T11-2  plus anti-T11-3  pair was a strong  stimulator  of 
proliferation  (data  not  shown).  CD2E1  plus  CD2E3  also 
stimulated proliferation, as did CD2E1 plus anti-T11-3 (Fig. 
8 A). However, anti-T11-1,  whether combined with CD2E3 
or with anti-T11-3, either had no effect or had a mild inhibi- 
tory effect on baseline proliferation. Therefore, while CD2E1 
and anti-T11-1  had identical effects on proliferation individ- 
ually but different effects when part of a stimulatory pair, 
the converse was true for CD2E3 and anti-T11-3.  When IL-12 
or IL-2 was added either to the anti-T11-2  plus anti-T11-3 
or to the CD2E1 plus CD2E3 pair,  little to no further aug- 
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Figure 6.  Anti-CD58 selectively  inhibits IL-12-induced  proliferation and 
IFN-3' production by PHA-activated T cells. Anti-CD58 was used as a 
1:400 dilution of ascites. Results are representative of three experiments 
for proliferation and two experiments for IFN-3, production. -0--, IL- 
l2;  -1-,  II:12  plus  anti-CD58;  .... O"",  II:2;  .... 0"',  IL2  plus 
anti-CD58. 
mentation was observed (data not shown). However, when 
used  in  combination with cytokine,  the  anti-T11-1 plus 
anti-T11-3 pair synergized strongly with I1:12 at concentra- 
tions ranging from 0.1 to 1 nM (Fig. 8 B). Maximal stimu- 
lation achieved by IL-12 closely approximated that obtained 
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Figure 7.  CTLA-4-Ig does not inhibit IL-12- or IL-2-induced prolifer- 
ation of activated T cells. Purified CTLA-4-Ig  was used at 5/zg/ml. Results 
with an isotype-matched control did not differ significantly from CTLA- 
4-1g (data not shown).  Results  are representative of two experiments. 
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plus CTLA-4-Ig. 
A 
125000. 
i  75000" 
5~00' 
~"  8" 
CD2  ANTIBODY 
150000- 
100000- 
50000- 
Figure 8. 
0  ,  i  , 
[IL-121  (pM) 
(A) CD2R antibodies can stimulate proliferation of T cells 
when paired with CD2E1, but fail to stimulate proliferation when paired 
with anti-T11-1. Day 4 PHA-activated T cells were incubated with the 
indicated mAbs without the addition of Ib12 or IL-2 in a 48-h prolifera- 
tion assay. Data with the CD2R antibodies used alone are compared with 
that obtained with each CD2R mAb paired with anti-T11-1 or CD2E1. 
Results are representative of three experiments. (B) Anti-T11-1 plus anti- 
Tll-3 synergizes with IL-12 in inducing  the proliferation of PHA-activated 
T cells. Results are representative of three experiments. 'K~, no mAb; 
.... I"",  Tl1-1 plus Tll-3. 
with I1:2, though 100-1,000-fold less I1:12 was required. No 
significant synergy was observed with I1:2 (data not shown). 
Anti-T11-2 Plus Anti-T11-3 Synergizes with ILl2 in Inducing 
T Cell IFN-7 Production.  After observing the synergy be- 
tween a specific pair of CD2 antibodies and I1:12 with re- 
gard to proliferation, we investigated whether such synergy 
could be shown for IFN-'y production as well. Anti-T11-2 
plus anti-T11-3, when used without cytokine, stimulated T 
cell IFN-'y production to a level  approximating maximal stim- 
ulation with I1:12 (Fig. 9). However, it strongly synergized 
with I1:12, augmenting maximal IFN-'y production 20-fold 
at an I1:12 concentration of 1 pM and 40-fold at >~10 pM. 
The effect observed with IL-2 was largely additive, with rela- 
tively weak synergy apparent only at a concentration of I nM. 
The Proliferative Response of T Cells to ILl2 Is Diminished 
in the Absence of APCs.  The observation that CD2 anti- 
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Figure  9.  Anti-T11-2 plus anti-Tll-3 synergizes with 1I.-12 in inducing  Figure  10.  (A) T  cell response to 1612 is diminished  in the absence 
the production of IFN-',/by PHA-activated T cells. Baseline IFN-v produc-  of APCs.  Sorted CD5 +  Ia- T cells were activated with PHA for 4 d be- 
tion in the absence of exogenous cytokine was 50/~g/ml. Maximal IFN-'y  fore incubation with I1:12 or 11:2 at the indicated concentrations  in a 48-h 
production was 450 #g/ml for IL-12 alone and 70/~g for I1:2 alone. Results  proliferation assay. The results are compared with an assay performed under 
are representative of two experiments.  Stippled bar, no mAb; shaded bar,  identical conditions  using PHA-activated  whole PBMC from the same 
Tll-2 plus Tll-3.  donor. Proliferation in the absence of'exogenous cytokine was 800  _+  150 
cpm for the sorted T cells and 5,000  _+  450 cpm for unsorted  T  cells. 
Results  are representative  of two experiments.  -C]-, II.,12 plus APCs; 
bodies that block the CD2/CD58 interaction interfere with  .... I1""',  I1:12 minus APCs; --O--, II:2 plus APCs; --t--, I1:2 minus 
APCs.  (B) Anti-T11-1 plus anti-T11-3 restores T  cell responsiveness to 
T cell responsiveness to IL12 suggested that a cell-cell inter-  I1:12 in the absence of APCs. Sorted CD5 § Ia-  T  cells were incubated 
action between activated T cells and a second cell type bearing  with I1:12 or I1:2 in the presence or absence of the indicated CD2 mAbs 
CD58 might  be central  to II.-12-mediated  T  cell stimula-  in a 48-h proliferation  assay. Anti-T11-1 was used as ascites at 1:400 dilu- 
tion. While this CD2/CD58  interaction could occur between  tion, and purified anti-T11-3 was used at  10/~g/ml. Proliferation  with 
T cells, we hypothesized that, in vivo, it would most likely  anti-T11-1  plus anti-T11-3, in the absence of exogenous cytokine, was 1,500 
_+  200 cpm. Results are representative of two experiments.  -C3-, 11:12; 
be occurring between T  cell and APC (either macrophages  .... II'"', 11:12 plus Tl1-1 plus Tll-3; --O-; I1:2; --O-; I1:2 plus Tl1-1 
or B cells),  since the latter expresses CD58 and is the pri-  plus Tll-3. 
mary source of I1:12 (2). To test this hypothesis, we inves- 
tigated whether  the removal of APCs from PBMC before 
activation with PHA affected the ability of PHA-activated  ative response to I1:12 was augmented in a synergistic fashion, 
T  cells to respond to I1:12.  Since both macrophages and B  with maximal proliferation equaling that observed with I1:2. 
cells,  but not resting  T  cells,  express MHC class  II mole-  This antibody pair had no effect on I1:2-induced proliferation. 
cules,  we rigorously depleted PBMC of APCs by sorting 
for CD5+Ia -  cells .and  subsequently activated these APC- 
depleted T cells with PHA in the same manner used for whole  Discussion 
PBMC. As shown in Fig.  10 A,  the proliferative response  In this report, we have used various mAbs specific for CD2 
of APC-depleted T cells to II.-12 was greatly diminished when  to demonstrate that this surface glycoprotein plays a central 
compared with whole PBMC obtained from the same donor  role in the response of T cells to IL-12, Although resting T 
and preactivated in the same manner.  Even at an II.-12 con-  cells are capable of being weakly stimulated by I1:12 to pro- 
centration of 1 nM, there was a fivefold reduction in prolifer-  duce IFN-'y, preactivation with a mitogen such as PHA is 
ation.  Notably,  the proliferative response to  II_,2 was not  necessary for up-regulation of the I1:12R (26), leading then 
significantly  altered  in  the  absence  of  APCs.  CD2E1,  to proliferation and augmented IFN-3, production in response 
anti-T11-1,  and CD2E3 were able to further inhibit I1:12-in-  to I1:12.  The most notable finding in this current  study is 
duced proliferation without affecting the response to II.,2 (data  the dependence of preactivated T cells on the interaction of 
not shown). As shown in Fig.  10 B, when anti-T11-1  plus  CD2  with  at  least  one ligand,  CD58,  for  I1:12-induced 
anti-T11-3 was added to the APC-depleted cells, the prolifer- 
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observed for Ib2. The selective inhibitory effect of our anti- 
bodies recognizing the adhesion domain of CD2,  coupled 
with the observation that anti-CD58 has an identical effect, 
is compelling evidence that the CD2/CD58 interaction gov- 
erns the response of T  cells to II~12. The lack of inhibition 
by anti-Tll-2, an antibody which does not block E-rosetting, 
further supports the hypothesis that a specific CD2/CD58 
interaction is required for T  cell responsiveness to IL-12. In 
contrast to the Ib12-specific inhibitory effect of CD2 anti- 
bodies, interference with the CD28/B7 interaction did not 
alter the response to either Ib12  or Ib2. 
The IL-12-specific inhibition observed with CD2E3,  our 
new antibody which recognizes a unique CD2R epitope and 
does not interfere with E-rosetting, raises the possibility that 
the CD2/CD58  interaction is not the sole determinant of 
T cell responsiveness to IL.12. One explanation for the func- 
tional effect of CD2E3 is that, by binding to CD2, it pre- 
vents an essential conformational change in CD2 normally 
induced by the CD2/CD58  interaction. Because CD2E3 is 
an IgM antibody,  its large size could be the key factor in 
interfering with a change in conformation. Anti-T11-3, on 
the other hand,  may induce an activating conformational 
change upon binding to CD2, accounting for its ability to 
stimulate T  cells when used alone.  A  second plausible in- 
terpretation is that CD2 may interact with a second, uniden- 
tiffed ligand X through CD2R, and this then cooperates with 
the CD2/CD58 interaction in stimulating a preactivated T  cell 
and priming it  for responsiveness to IL-12. In this model, 
CD2E3  would  be  a  ligand  X  antagonist,  blocking  the 
CD2R/X interaction that would ordinarily be cooperating 
with the CD2/CD58 interaction. Anti-T11-3,  however, would 
be a ligand X  agonist,  stimulating CD2 in a manner that 
cooperates with  CD2/CD58  and results in proliferation. 
In addition to demonstrating that individual antibodies to 
CD2 and CD2R can inhibit II.-12 activation, we showed how 
pairs of CD2R plus CD2 antibodies can synergize strongly 
with I1.-12 in inducing proliferation and IFN-3~ production. 
Some synergy could also be detected with II.-2, but this was 
far weaker and occurred over a narrower concentration range. 
As we have demonstrated, different pairs of CD2 plus CD2R 
mAbs varied in their ability to augment proliferation in the 
absence of exogenous cytokine. It is not clear why anti-T11-1 
failed to overtly stimulate cells in the absence of added cytokine 
when paired with CD2K mAbs, but this further underscores 
the  point  that  CD2E1  and  anti-T11-1  (like  CD2E3  and 
anti-T11-3)  recognize two unique epitopes of CD2.  With 
regard to proliferation,  strong synergy was observed with 
anti-T11-1 plus anti-T11-3,  perhaps indicating that CD2 per- 
turbation by these antibodies can still activate cells in a manner 
that primes them for responsiveness to II.-12 without overtly 
stimulating  them  in  the absence of cytokine.  For  IFN-3/ 
production,  synergy  with  II.-12 was  demonstrable  with 
anti-T11-2 plus anti-Tll-3, because this particular function, 
unlike proliferation, was not maximally stimulated by these 
antibodies alone. Taken together with the IL-12-specific  in- 
hibitory effect of single antibodies, the data favor the hypothesis 
that CD2 activation not only influences whether or not a 
T  cell can respond to II.-12 but also determines the magni- 
tude of the response. 
Since we  hypothesize  that  CD2  stimulation,  mediated 
through its interaction with CD58,  is required for T  cells 
to respond to IL-12, it is important to know which cell bearing 
the appropriate ligand interacts with T cells in this capacity. 
Although many different hematopoietic cell types express 
CD58  (28),  including T  cells,  we bdieve that  the APC is 
a good candidate based on our data demonstrating a marked 
decrease in T cell responsiveness to Ib12 when APCs are re- 
moved before PHA activation. In particular, the macrophage 
would fit this role well based on its ability to present antigen 
and augment its production of I1.-12 in response to IFN-3' 
(29). Although a T cell, after interacting with an APC bear- 
ing antigen, B7, and CD58, is able to perpetuate activation 
through IL-2 on its own through an autocrine pathway (30), 
this is not  the case for Ib12-mediated activation.  Since T 
cells cannot produce IL-12 (2), they are reliant on the macro- 
phage  for  Ib12-mediated  activation  through  a  paracrine 
pathway. As illustrated in Fig.  11, we hypothesize from our 
data that CD2 may assume a central position in an IL-12/IFN~ 
positive feedback loop between activated T  cell and APC. 
In this model, stimulation through CD2,  occurring when 
the adhesion domain of CD2 engages CD58 on an APC, 
confers on the T  cell responsiveness to Ib12.  Although in 
our assays T  cells were preactivated with PHA, in vivo this 
preactivation would most likely result from antigen recogni- 
tion  through  the  T  cell  receptor  along  with  B7/CD28 
costimulation. Once this CD2-mediated functional link be- 
tween activated T cell and APC is established, APC-derived 
Ib12 can act on the CD2-primed T  cell to induce maximal 
IFN-~/production and proliferation.  The T cell-derived IFN-3, 
would then, in turn, stimulate the APC to kill its intracd- 
lular pathogen and produce more IL-12. By ensuring that the 
T cell responds to Ib12 only when intimately associated with 
the source, this would be an ef~cient mechanism by which 
a T  cell could perpetuate its activation by Ib12  and most 
effectively deliver IFN-3, to its primary target, the macrophage. 
Figure  11.  CD2 provides the key functional link between T cell and 
APC required for T cell responsiveness to Ib12. This hypothetical model 
shows how the interaction of CD2 with CD58 would play a key role in 
the generation of an IL-12/IFN-',/positive  feedback loop between T cell 
and APC. 
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apparent specificity the CD2/CD58  interaction has in con- 
trolling the T cell response to I1.-12, as contrasted with IL-2. 
This functional pairing between a cytokine receptor and a 
distinct adhesion molecule may allow a hematopoietic cell 
to modulate its responsiveness to a particular cytokine based 
on an ability to discriminate between a microenvironment 
that can and one that cannot optimally support and benefit 
from such a response. The molecular basis by which the CD2/ 
CD58 interaction controls IL-12 responsiveness now needs 
to be defined. Whatever the mechanism, the CD2/CD58 in- 
teraction will most likely be involved, along with II.-12, in 
shifting the immune response along a Thl pathway. 
Several interesting parallels  to the II~12/CD2-CD58  in- 
teraction exist outside of the hematopoietic system. For ex- 
ample, in a human pancreatic cell line, the interaction of a 
specific class of integrins (olvfl3) with its ligand, vitronectin, 
enhances the growth response to insulin (31). At the molec- 
ular level,  stimulation through the insulin receptor results 
in the association of this integrin with tyrosine-phosphorylated 
insulin receptor substrate 1 and several other signaling mole- 
cules (31),  suggesting a cooperative interaction between a 
growth factor receptor and adhesion molecule at the level 
of signal transduction. In rat cerebellar neurons, it has been 
demonstrated  that  neurite  outgrowth  stimulated  by  the 
homophilic  binding  of neuronal  cell  adhesion  molecules 
(CAMs) to N-CAM, N-cadherin, or L1 involves activation 
of the fibroblast growth factor receptor (FGFR) (32). In this 
system, it appears as though a direct physical interaction be- 
tween specific CAMs and the FGFR can result in FGFR- 
mediated signal transduction, even in the absence of soluble 
FGF  (32). 
In summary, we have demonstrated that antibodies directed 
at specific regions of CD2 influence the response of T  cells 
to IL12. To explain this novel effect, we have proposed a model 
in which CD2 provides a critical functional link for an Ib 
12/IFN-3, positive feedback loop between T cell and APC. 
Along with providing a new direction for investigating the 
functional significance of CD2,  our findings shed light on 
how the functional effect of a particular cytokine may be 
influenced not only by the presence or absence of a specific 
receptor, but also by specific, cooperative cell-cell interactions 
designed to maximize and perpetuate a particular immune 
response. Since our model is centered on a cooperative inter- 
action between CD2 and the IL-12R,  future investigations 
of the molecular basis  governing this proposed interaction 
may yield valuable information regarding the signaling path- 
ways of both CD2 and the IL-12R and how they differ from 
signaling via the IL-2R. From a clinical standpoint, since II:2 
is capable of activating T cells, NK cells, and monocytes in 
the absence of costimulation, it has been used with the as- 
sumption that parenteral administration would systemically 
activate those components of the immune system bearing 
receptors for IL-2. That this indeed occurs has been demon- 
strated both by in vitro studies of lymphocytes derived from 
patients receiving I1.,2 (33, 34) and by the side effects (which 
can include fever, hypotension, myalgias, and capillary leak 
syndrome) reflecting IL2-induced cytokine production (34, 
35). On the other hand, if IL-12 is active on T cells primarily 
in the presence of CD2 stimulation, as our findings suggest, 
then the effectiveness of systemic administration will depend 
heavily on the microenvironment, with T  cells responding 
to II~12 only if tumor antigens or antigens from infectious 
pathogens are presented along with the appropriate ligand(s) 
for CD2. Furthermore, the side effects of II.,12 might be con- 
siderably less compared with IL-2 if IL-12-induced cytokine 
production is not systemically stimulated. Whether NK cells 
also require CD2 stimulation to respond to II,-12 remains to 
be investigated, although it seems less likely since an interac- 
tion with APCs is not required for antigen recognition. As 
IIA2 holds considerable promise, based on animal studies, 
for the treatment of both oncologic disorders (36) and infec- 
tious diseases (29),  a better knowledge of those cellular in- 
teractions cooperating with II~12 will help in translating the 
observed immunomodulatory effects of IL12 into a clinically 
beneficial treatment modality. 
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